



Chia Po Ying

Head of NCID Research Office

Consultant, Department of Infectious Diseases, TTSH and NCID

Research/Innovation Interests:

- Dengue and Emerging Infectious Diseases
- Antimicrobial Resistance
- General Infectious Diseases
- HIV Medicine

Email: Po_Ying_Chia@ncid.sg ; Po_Ying_Chia@ttsh.com.sg

Biography

Dr Chia Po Ying currently an Infectious Disease consultant at the National Centre for Infectious Diseases and Tan Tock Seng Hospital and Assistant Professor with Lee Kong Chian School of Medicine (LKCMedicine), Nanyang Technological University (NTU). She obtained her PhD in the pathogenesis of dengue from LKCMedicine (NTU), Masters of Medicine (Internal Medicine) from Yong Loo Lin School of Medicine (YLLSOM) National University of Singapore (NUS), and MBBS from YLLSOM NUS. She is also a member of the Royal College of Physicians of the United Kingdom and has completed her clinical specialty training in Infectious Diseases.

Dr Chia's research work has been supported by grants from the National Medical Research Council (NMRC) Research Training Fellowship and the NHG-NTU Clinician Scientist Fellowship. She has a keen interest in dengue fever, emerging and re-emerging infectious diseases, as well as antimicrobial resistance. As a capable clinician scientist, Po Ying is well poised to take on the headship of NCID Research Office in IDRTO.

Selected Publications

- ACTIV-3/TICO Bamlanivimab Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnowar BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. *Ann Intern Med.* 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507
https://www.acpjournals.org/doi/full/10.7326/M21-3507?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(21\)00384-2/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00384-2/fulltext)
- Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J, De Wang L, Chia WN, Tiu C, Chan M, Ling LM, Vasoo S, Abdad MY, Chia PY, Lee TH, Lin RJ, Sadarangani SP, Chen MI, Said Z, Kurupatham L, Pung R, Wang LF, Cook AR, Leo YS, Lee VJ. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. *Lancet Infect Dis.* 2021 Mar;21(3):333-343. doi: 10.1016/S1473-3099(20)30833-1.
[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30833-1/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30833-1/fulltext)
- Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, Cui L, Kalimuddin S, Chia WN, Tan CW, Chai LYA, Tan SY, Zheng S, Lin RTP, Wang L, Leo YS, Lee VJ, Lye DC, Young BE. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. *Clin Microbiol Infect.* 2022 Apr;28(4):612.e1-612.e7. doi: 10.1016/j.cmi.2021.11.010
<https://www.sciencedirect.com/science/article/pii/S1198743X21006388>
- Poh XY, Tan CW, Lee IR, Chavatte JM, Fong SW, Prince T, Hartley C, Yeoh AYY, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim C, Teo J, Lim DRX, Chia W, Hiscox JA, Ng LFP, Ren EC, Lin RTP, Renia L, Lye DC, Wang LF, Young BE. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. *Clin Infect Dis.* 2022 Dec 19;75(12):2088-2096. doi: 10.1093/cid/ciac345
<https://academic.oup.com/cid/article/75/12/2088/6583615>
- Teo A, Chua CLL, Chia PY, Yeo TW. Insights into potential causes of vascular hyperpermeability in dengue. *PLoS Pathog.* 2021 Dec 9;17(12):e1010065. doi: 10.1371/journal.ppat.1010065. PMID: 34882753; PMCID: PMC8659665.
<https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010065>

- Chia PY, Htun HL, Leo YS, Lye DC. Safety of temporary interruption of antiplatelet therapy in dengue fever with thrombocytopenia. J Infect. 2021 Feb;82(2):270-275. doi: 10.1016/j.jinf.2020.10.038. Epub 2020 Nov 30. PMID: 33271172. [https://www.journalofinfection.com/article/S0163-4453\(20\)30730-1/fulltext](https://www.journalofinfection.com/article/S0163-4453(20)30730-1/fulltext)
- Chia PY, Teo A, Yeo TW. Association of Neutrophil Mediators With Dengue Disease Severity and Cardiac Impairment in Adults. J Infect Dis. 2022 Nov 28;226(11):1974-1984. doi: 10.1093/infdis/jiac383. PMID: 36208158. <https://academic.oup.com/jid/article-abstract/226/11/1974/6706606?redirectedFrom=fulltext&login=false>
- Archuleta S, Chia PY, Wei Y, Syed-Omar SF, Low JG, Oh HM, Fisher D, Ponnampalavanar SSL, Wijaya L, Kamarulzaman A, Lum LCS, Tambyah PA, Leo YS, Lye DC. Predictors and Clinical Outcomes of Poor Platelet Recovery in Adult Dengue With Thrombocytopenia: A Multicenter, Prospective Study. Clin Infect Dis. 2020 Jul 11;71(2):383-389. doi: 10.1093/cid/ciz850. PMID: 31626692 <https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciz850>
- Teo A, Chia PY, Yeo TW. Performance of soluble suppressor of tumorigenicity-2 as a prognostic marker for severe dengue in adults. J Infect. 2023 Oct 12:S0163-4453(23)00534-0. doi: 10.1016/j.jinf.2023.10.003. Epub ahead of print. PMID: 37838254. [https://www.journalofinfection.com/article/S0163-4453\(23\)00534-0/fulltext](https://www.journalofinfection.com/article/S0163-4453(23)00534-0/fulltext)
- Teo A, Le CTT, Tan T, Chia PY, Yeo TW. Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults. Clin Infect Dis. 2024 Mar 20;78(3):788-796. doi: 10.1093/cid/ciad637. [Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults | Clinical Infectious Diseases | Oxford Academic \(oup.com\)](https://academic.oup.com/cid/article-abstract/78/3/788/7611111)

Notable Research/Innovation Awards & Grants from Past 5 Years

Name of Awards & Grants	Year Obtained
NMRC Research Training Fellowship (RTF) The Role of the Endothelial Glycocalyx, Mast cells and Vascular Nitric Oxide in the Pathogenesis of Dengue	2018
NHG-LKCMedicine Clinician Scientist Fellowship (CSF)	2018

Translating Research Into Healthcare

- CNA Explains: Why is Singapore at risk of a surge in dengue cases? Published on 08 Sep 2023. <https://www.channelnewsasia.com/singapore/dengue-clusters-surge-aedes-mosquito-toa-payoh-3753571>